Maruta H - Search Results

1

An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin).

Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H. Tikoo A, et al. Among authors: maruta h. J Biol Chem. 1994 Sep 23;269(38):23387-90. J Biol Chem. 1994. PMID: 8089100 Free article.

M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M., Munro, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. ...Like neurofibromatosis type 1 (NF1) fragments (Nur-E-Kamal, M. S. A., Varga, M., and Maruta, H. (1993) J. …

M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M., Munro, D., Bove, C., Haines, J. L., Martuza, R. …

2

A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.

Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J, Maruta H. Hirokawa Y, et al. Among authors: maruta h. Cancer J. 2004 Jan-Feb;10(1):20-6. doi: 10.1097/00130404-200401000-00006. Cancer J. 2004. PMID: 15000491

3

The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype.

Fridman M, Tikoo A, Varga M, Murphy A, Nur-E-Kamal MS, Maruta H. Fridman M, et al. Among authors: maruta h. J Biol Chem. 1994 Dec 2;269(48):30105-8. J Biol Chem. 1994. PMID: 7982912 Free article.

4

The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype.

Nur-E-Kamal MS, Varga M, Maruta H. Nur-E-Kamal MS, et al. Among authors: maruta h. J Biol Chem. 1993 Oct 25;268(30):22331-7. J Biol Chem. 1993. PMID: 8226742 Free article.

5

The GTPase and Rho GAP domains of p190, a tumor suppressor protein that binds the M(r) 120,000 Ras GAP, independently function as anti-Ras tumor suppressors.

Wang DZ, Nur-E-Kamal MS, Tikoo A, Montague W, Maruta H. Wang DZ, et al. Among authors: maruta h. Cancer Res. 1997 Jun 15;57(12):2478-84. Cancer Res. 1997. PMID: 9192829

6

G proteins, phosphoinositides, and actin-cytoskeleton in the control of cancer growth.

Maruta H, He H, Tikoo A, Vuong T, Nur-E-Kamal M. Maruta H, et al. Microsc Res Tech. 1999 Oct 1;47(1):61-6. doi: 10.1002/(SICI)1097-0029(19991001)47:1<61::AID-JEMT6>3.0.CO;2-Y. Microsc Res Tech. 1999. PMID: 10506762 Review.

7

Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445.

Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H. Tikoo A, et al. Among authors: maruta h. Cancer J Sci Am. 1999 Sep-Oct;5(5):293-300. Cancer J Sci Am. 1999. PMID: 10526670

8

Cytoskeletal tumor suppressors that block oncogenic RAS signaling.

Maruta H, He H, Tikoo A, Nur-e-Kamal M. Maruta H, et al. Ann N Y Acad Sci. 1999;886:48-57. doi: 10.1111/j.1749-6632.1999.tb09399.x. Ann N Y Acad Sci. 1999. PMID: 10667202 Review.

9

The anti-RAS cancer drug MKT-077 is an F-actin cross-linker.

Maruta H, Tikoo A, Shakri R, Shishido T. Maruta H, et al. Ann N Y Acad Sci. 1999;886:283-4. doi: 10.1111/j.1749-6632.1999.tb09437.x. Ann N Y Acad Sci. 1999. PMID: 10667240 No abstract available.

10

Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077.

Tikoo A, Shakri R, Connolly L, Hirokawa Y, Shishido T, Bowers B, Ye LH, Kohama K, Simpson RJ, Maruta H. Tikoo A, et al. Among authors: maruta h. Cancer J. 2000 May-Jun;6(3):162-8. Cancer J. 2000. PMID: 10882332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters